Renal Cell Carcinoma Clinical Trials (2026): 293 Recruiting Interventional Studies

Last updated: April 2, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Stage

First-Line (Treatment-Naive Advanced/Metastatic)

IO+TKI combinations are standard first-line. Trials explore triplets and novel combinations:

• IO+TKI optimization:
  • NCT07011719 - Casdatifan + Cabozantinib vs Placebo + Cabozantinib in advanced ccRCC (Phase 3)
  • NCT07239596 - SHR-8068 + Adebrelimab + anti-tumor drugs in advanced RCC (Phase 1b/2)
• IO de-escalation:
  • NCT05078047 - IO every 3 months vs standard dosing in responding patients (Phase 3)
  • NCT07175480 - PET/CT-directed treatment-free intervals for IMDC favorable/intermediate risk (Phase 2)

After IO Progression (Second-Line+)

A major unmet need — what to do after IO+TKI failure:

• HIF-2 inhibitor combinations:
  • NCT07227402 - Belzutifan + Zanzalintinib (next-gen TKI) for recurrent RCC after adjuvant therapy (Phase 3)
  • NCT06234605 - HC-7366 + Belzutifan in RCC (Phase 1/2)
  • NCT07049926 - KEYMAKER-U03: Combination therapies for RCC recurrent after anti-PD-(L)1 (Phase 2)
• Novel combinations:
  • NCT06730672 - Voronib + Everolimus after IO failure (Phase 2)
  • NCT07469683 - SLC-3010 + Axitinib vs Axitinib monotherapy second-line ccRCC (Phase 2)
  • NCT03592472 - RENAVIV: Pazopanib ± Abexinostat (HDACi) in advanced RCC (Phase 3)
• Radiopharmaceuticals:
  • NCT07197580 - 177Lu-TLX250 (CAIX-targeted) in advanced relapsed/recurrent ccRCC (Phase 3)

Neoadjuvant / Perioperative

• NCT05738694 - Neoadjuvant Axitinib + PD-1 to improve DFS (Phase 3)
• NCT05969496 - Neoadjuvant Pembrolizumab + Axitinib for IVC tumor thrombus (Phase 2)
• NCT05319015 - Neoadjuvant Lenvatinib + Pembrolizumab for IVC tumor thrombus (Phase 2)
• NCT07386158 - Pucotenlimab + Vorolanib neoadjuvant for ccRCC (Phase 2)
• NCT07187778 - BLAZE: Belzutifan or Pembrolizumab vs combination neoadjuvant in ccRCC (Phase 2)

Adjuvant (After Surgery)

• NCT03288532 - RAMPART: Multi-arm adjuvant trial (Phase 3)
• NCT06661720 - Tivozanib + Pembrolizumab after surgery to remove all known sites (Phase 3)
• NCT06005818 - MRD-guided adjuvant therapy (Phase 2)

Oligometastatic / Radiation Approaches

• NCT06467097 - Systemic therapy ± radiotherapy in oligometastatic RCC (Phase 3)
• NCT06726421 - STROKER: Systemic therapy ± SBRT for oligometastatic kidney cancer (Phase 3)
• NCT06255223 - Multimodal radiotherapy for RCC progressed after IO (Phase 2)

Novel Approaches

• CAR-T / cellular therapy: NCT02830724 - CD70-targeting CAR-T for CD70-expressing cancers including RCC; NCT04897321 - B7-H3 CAR-T; NK cell therapies (NCT07410676 - EBNK-001 allogeneic NK cells)
• Radiopharmaceuticals: 177Lu-TLX250 targeting CAIX (carbonic anhydrase IX), highly expressed in ccRCC
• Neoantigen vaccines: NCT05269381 - Personalized neoantigen peptide vaccine + Pembrolizumab
• Cytoreductive surgery + IO: NCT04510597 - PROBE: IO+TKI ± nephrectomy in metastatic RCC (Phase 3)

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.

Frequently Asked Questions